Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Capital Expenditures (2021 - 2025)

Prime Medicine filings provide 5 years of Capital Expenditures readings, the most recent being -$4.1 million for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 5.1% to -$4.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $114000.0, a 90.12% decrease, with the full-year FY2025 number at $114000.0, down 90.12% from a year prior.
  • Capital Expenditures hit -$4.1 million in Q4 2025 for Prime Medicine, down from $247000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $8.2 million in Q4 2023 to a low of -$5.6 million in Q3 2022.
  • Median Capital Expenditures over the past 5 years was $1.1 million (2022), compared with a mean of $467470.6.
  • Biggest five-year swings in Capital Expenditures: soared 8193.94% in 2023 and later plummeted 152.97% in 2024.
  • Prime Medicine's Capital Expenditures stood at -$3.0 million in 2021, then skyrocketed by 103.28% to $99000.0 in 2022, then soared by 8193.94% to $8.2 million in 2023, then plummeted by 152.97% to -$4.3 million in 2024, then increased by 5.1% to -$4.1 million in 2025.
  • The last three reported values for Capital Expenditures were -$4.1 million (Q4 2025), $247000.0 (Q3 2025), and $1.6 million (Q2 2025) per Business Quant data.